Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AMGN 
Amgen Inc (AMGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: AMGN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
32 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $322.88
1 Year Target Price $322.88
| 10 | Strong Buy |
| 5 | Buy |
| 14 | Hold |
| 1 | Sell |
| 2 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.37% | Avg. Invested days 50 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 186.02B USD | Price to earnings Ratio 26.74 | 1Y Target Price 322.88 |
Price to earnings Ratio 26.74 | 1Y Target Price 322.88 | ||
Volume (30-day avg) 32 | Beta 0.46 | 52 Weeks Range 245.31 - 345.66 | Updated Date 12/1/2025 |
52 Weeks Range 245.31 - 345.66 | Updated Date 12/1/2025 | ||
Dividends yield (FY) 2.73% | Basic EPS (TTM) 12.92 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.47% | Operating Margin (TTM) 34.15% |
Management Effectiveness
Return on Assets (TTM) 7.71% | Return on Equity (TTM) 81.71% |
Valuation
Trailing PE 26.74 | Forward PE 15.7 | Enterprise Value 231165532603 | Price to Sales(TTM) 5.17 |
Enterprise Value 231165532603 | Price to Sales(TTM) 5.17 | ||
Enterprise Value to Revenue 6.43 | Enterprise Value to EBITDA 13.99 | Shares Outstanding 538480671 | Shares Floating 537123700 |
Shares Outstanding 538480671 | Shares Floating 537123700 | ||
Percent Insiders 0.21 | Percent Institutions 83.8 |
Upturn AI SWOT
Amgen Inc
Company Overview
History and Background
Amgen Inc. was founded in 1980 as Applied Molecular Genetics. It has grown to become one of the world's largest biotechnology companies, focusing on human therapeutics.
Core Business Areas
- General Medicine: Includes products focused on cardiovascular diseases, metabolic disorders, and general medicine practices.
- Oncology: Focuses on therapies to treat cancer and related complications.
- Hematology: Includes treatments for blood disorders.
- Inflammation: Therapies targeting inflammatory diseases.
Leadership and Structure
Robert Bradway is the Chairman and CEO. The company has a hierarchical structure with various departments reporting to executive leadership.
Top Products and Market Share
Key Offerings
- Enbrel: Enbrel is a TNF blocker used to treat autoimmune diseases like rheumatoid arthritis and psoriasis. Competitors include Humira (ABBV) and Remicade (JNJ). Market share data is not available in percentage but this is a top revenue driver for Amgen.
- Neulasta/Neupogen: These are growth factors used to stimulate white blood cell production in cancer patients undergoing chemotherapy. Competitors include biosimilars from Novartis (NVS) and Mylan (now Viatris, VTRS). Market share data is not available in percentage but this is a top revenue driver for Amgen.
- Prolia/Xgeva: Prolia and Xgeva are used to treat osteoporosis and prevent skeletal-related events in cancer patients, respectively. Competitors include bisphosphonates and other bone-modifying agents. Market share data is not available in percentage but this is a top revenue driver for Amgen.
- Otezla: Otezla is a small molecule inhibitor used to treat psoriasis and psoriatic arthritis. Competitors include TNF inhibitors and other systemic therapies. Market share data is not available in percentage but this is a top revenue driver for Amgen.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and patent protection. It is marked by continuous innovation and competition.
Positioning
Amgen is a leading biotechnology company with a strong portfolio of innovative therapies. It has a significant market presence in oncology, hematology, and inflammation. Its competitive advantage lies in its research capabilities, manufacturing expertise, and global reach.
Total Addressable Market (TAM)
The global biopharmaceutical market is projected to reach over $500 billion. Amgen is positioned to capture a significant share of this market through its diverse product portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Strong product portfolio
- Extensive research and development capabilities
- Global presence
- Proven track record of innovation
- Strong financial performance
Weaknesses
- Reliance on key products facing biosimilar competition
- High R&D expenses
- Patent expiration risks
- Regulatory hurdles
- Pricing pressures
Opportunities
- Expansion into new therapeutic areas
- Development of biosimilars
- Strategic acquisitions and partnerships
- Emerging markets growth
- Advancements in drug delivery technologies
Threats
- Increasing competition from biosimilars
- Drug pricing regulations
- Patent challenges
- Economic downturns
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- MRK
- PFE
Competitive Landscape
Amgen faces intense competition from other large pharmaceutical and biotechnology companies. Its advantages include its established brand, strong R&D pipeline, and global reach. However, it also faces challenges from biosimilar competition and drug pricing pressures.
Major Acquisitions
Horizon Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 27800
- Strategic Rationale: To expand Amgen's portfolio in rare diseases and immunology.
Growth Trajectory and Initiatives
Historical Growth: Amgen has experienced significant growth over the past decades, driven by successful product launches and strategic acquisitions.
Future Projections: Analysts project moderate revenue growth for Amgen, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent initiatives include the acquisition of Horizon Therapeutics and investments in innovative drug delivery technologies.
Summary
Amgen is a strong biotechnology company with a robust product portfolio and a commitment to innovation. However, it faces challenges from biosimilar competition and pricing pressures. The acquisition of Horizon Therapeutics strengthens its position in rare diseases. Amgen needs to manage its pipeline effectively to offset losses from expiring patents and maintain its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not investment advice. Market share figures are estimates and may not be precise. Actual financial performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amgen Inc
Exchange NASDAQ | Headquaters Thousand Oaks, CA, United States | ||
IPO Launch date 1983-06-17 | Chairman, CEO & President Mr. Robert A. Bradway | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 28000 | Website https://www.amgen.com |
Full time employees 28000 | Website https://www.amgen.com | ||
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.